

HOTLINE: Effective August 16, 2021

New Test


3001839

## **Emery-Dreifuss Muscular Dystrophy Panel, Sequencing**

EDMD NGS



Additional Technical Information



Methodology: Massively Parallel Sequencing

**Performed:** Varies **Reported:** 3-6 weeks

Specimen Required: Collect: Lavender (EDTA) or Yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

**Reference Interval:** By report

## **Interpretive Data:**

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Genes Tested: EMD, FHL1, LMNA

**CPT Code(s):** 81479; 81404; 81406

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.